Five osmium (II) polypyridyl complexes of the general formula [Os (4, 7‐diphenyl‐1, 10‐
phenanthroline) 2L] 2+ were synthesized as photosensitizers for photodynamic therapy by …

The effectiveness of photodynamic therapy (PDT) is based on the triad effects of
photosensitizer (PS), molecular oxygen and visible light on malignant tumors. Such complex …

Photodynamic therapy (PDT) requires a photosensitizing agent, which can undergo visible
light activation, yielding reactive oxygen species and/or radical species. The key physical …

In this study, we reported a tamoxifen modified Ru (II) polypyridyl complex (Ru-tmxf) as an
estrogen receptor (ER) targeted photosensitizer. Ru-tmxf displays enhanced cellular uptake …

Ruthenium (II) polypyridyl complexes with long‐wavelength absorption and high singlet‐
oxygen quantum yield exhibit attractive potential in photodynamic therapy. A new …

Two-photon photodynamic therapy (TP-PDT) is a promising approach for the treatment of
cancer because of its better penetration depth and superior spatial selectivity. Here, we …

Novel photosensitizers with high reactive oxygen species generation and precise targeting
to tumors are crucial for photodynamic therapy (PDT). Here, a bromo-substituted …

Photodynamic therapy (PDT) is a promising new treatment modality for several diseases,
most notably cancer. In PDT, light, O2, and a photosensitizing drug are combined to produce …

Several mononuclear Ru (II) dyads possessing 1, 10-phenanthroline-appended
pyrenylethynylene ligands were synthesized, characterized, and evaluated for their potential …

A series of Ru (II) complexes bearing the tridentate 2, 6-di (quinolin-2-yl) pyridine (dqpy)
ligand were designed to undergo photoinduced ligand dissociation with red/near-IR light …